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T he outcomes of living donor liver transplantation (LDLT) for children with acute or chronic hepatic 
failure are known to be excellent.  Studies in pediatric 
liver transplantation have reported that the average 
recipient and graft survival rates of pediatric LDLT at 1 
and 4 years are 90% and 85%,  and 89% and 78%,  
respectively [1].  LDLT has enabled the optimization of 
the timing of transplantation and the shortening of the 
cold ischemic time (CIT),  contributing to a decreased 
mortality rate among pediatric candidates on the pedi-
atric waiting list [2 , 3].  Because the main procedure for 
donor surgery is a lateral segmentectomy or left hepa-
tectomy,  relatively better physical safety of the donor is 
also maintained [4].  LDLT has therefore been accepted 
as a powerful treatment for end-stage liver failure in 
children.  We conducted the present study to determine 
the factors that affect the survival of pediatric recipients 
in our cohort to identify measures and achieve further 
improvements in the survival of pediatric LDLT recipi-
ents.
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Living donor liver transplantation (LDLT) is the final therapeutic arm for pediatric end-stage liver diseases.  
Toward the goal of achieving further improvement in LDLT survival,  we investigated factors affecting recipient 
survival.  We evaluated the prognostic factors of 60 pediatric recipients (< 16 years old) who underwent LDLT 
between 1997 and 2015.  In a univariate analysis,  non-cholestatic (NCS) disease,  graft/recipient body weight 
ratio,  cold and warm ischemic times,  and intraoperative blood loss were significant factors impacting survival.  
In a multivariate analysis,  NCS disease was the only significant factor worsening survival (p= 0.0021).  One-and 
5-year survival rates for the cholestatic disease (CS,  n = 43) and NCS (n = 17) groups were 100% vs. 70.6% and 
97.4% vs. 58.8% (p= 0.004,  log-rank).  Intergroup comparisons revealed that CS was significantly associated with 
operation time,  cold ischemia,  hepatomegaly of the native liver,  and portal plasty.  These data suggest that a 
cirrhotic,  swollen,  artery-dominant liver did not increase graft size-related risks despite the surgical complex-
ity of preceding operations.  The NCS group’s poorer survival originated from recurrence of the primary disease 
and liver manifestation of systemic disease untreatable by transplantation.  Improving the survival of pediatric 
recipients requires intensive efforts to prevent primary disease relapse and more rapid diagnoses to exclude con-
traindications from NCS disease.
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Patients and Methods
Patients. This study was approved by the Ethics 
Committee at Okayama University Graduate School of 
Medicine,  Dentistry and Pharmaceutical Sciences and 
Okayama University Hospital (approval no. 1701-507) 
and was conducted in accordance with the Declaration 
of Helsinki.  We performed this retrospective cohort 
study for consecutive pediatric recipients under 16 years 
old who underwent an LDLT between August 1997 and 
December 2015 at Okayama University Hospital.  Sixty 
patients < 16 years old underwent 60 primary LDLTs.  
Prior to transplantation surgery,  written informed con-
sent regarding a future retrospective study was obtained 
from all of the patients.  At study enrollment,  all of the 
enrolled patients had been observed for > 1 year.  
Patients were observed preoperatively and followed-up 
after surgery as outpatients of Okayama University 
Hospital.
The patients were 27 boys and 33 girls (Table 1) 
ranging in age from 83 days to 16.5 years and with body 
weights (BWs) ranging from 3.9 kg to 66.4 kg.  We 
divided the patients’ primary diseases into two catego-
ries (cholestatic vs. non-cholestatic disease) according 
to final histological diagnoses: cholestatic disease (CS) 
including biliary atresia (BA; n = 37),  Alagille syn-
drome (n = 4),  and primary sclerosing cholangitis 
(PSC; n = 2); and non-cholestatic (NCS) disease 
including acute hepatic failure (n = 8),  metabolic dis-
ease (n = 4),  and tumor (n = 3,  hepatoblastoma: 2,  
chronic active EBV infection: 1),  and liver cirrhosis 
(LC; n = 2).
The patients received preoperative care as an outpa-
tient (n = 38),  on admission (n = 9),  or in an intensive 
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Table 1 Preoperative demographic data of the recipients and donors
Factors Values Range or %
Recipient
Gender (M/F) 27/33 45/55
Mean age (years,  range) 3.25±4.1 (89d-16.5y)
Mean body weight (kg),  (range) 13.5±11.2 (3.9-66.9)
Primary disease Cholestatic disease
(CS,  n＝43)
Biliary atresia 37 61.7%
Alagilleʼs syndrome 4 6.7%
Primary sclerosing cholangitis 2 3.3%
Non-cholestatic disease 
(NCS,  n＝17)
Acute hepatic failure (AHF) 8 13.3%
Metabolic disease 4 6.7%
Tumor 3 5.0%
Liver cirrhosis 2 3.3%
Preoperative condition Outpatient 38 63.3%
Admission 9 15.0%
ICU stay 13 21.7%
ABO blood type combination identical 40 66.7%
compatible 12 20.0%
incompatible 9 15.0%
Mean graft /body weight ratio (GRWR),  (range) 2.84±1.12 (1.00-6.16)
Preceding history of abdominal surgery 
(times)
0 20 33.3%
1 23 38.3%
2 17 28.3%
Donor
Mean age (years,  range) 37.8±11.6 (20.0-70.4)
Mean body mass index (kg/m2,  range) 22.4±3.0 (16.0-30.5)
Relation to recipient Grandfather 4 6.7%
Grandmother 6 10.0%
Father 29 48.3%
Mother 20 33.3%
Unrelated (father-in-law) 1 1.7%
care unit (ICU; n = 13).  The blood type of the donor 
was identical to that of the recipient in 39 cases,  com-
patible in 12,  and incompatible in 9.  The graft/recipi-
ent body weight ratio (GRWR) of the recipients ranged 
from 1.06 to 6.16 (median,  2.84 ± 1.12).
Clinical data. For the 60 enrolled pediatric 
recipients,  we evaluated the following demographic and 
clinical data as recipient preoperative factors: sex,  age,  
weight,  primary disease,  preoperative condition,  
ABO-blood type compatibility,  GRWR,  and preceding 
history of major abdominal surgery.  The donor factors 
evaluated were: age,  body mass index (BMI),  and 
familial relationships.  We also analyzed intraoperative 
factors including CIT,  warm ischemic time (WIT),  
microscopic reconstruction of the hepatic artery,  
requirement of portal plasty,  actual volume of 
explanted native liver,  operation time,  and blood loss.  
We examined the occurrence of acute cellular rejection 
(ACR),  steroid-resistant rejection (SRR),  cytomegalo-
virus (CMV) infection,  post-transplant lymphoprolif-
erative disease (PTLD),  and postoperative hospital stay 
as postoperative factors.  We then analyzed whether 
these perioperative factors affected recipient survival.
Transplant surgery. In each case,  the donor sur-
gery was started 1 h before the recipient surgery.  The 
details of the surgical procedures have been described 
[5 , 6].  Partial liver grafts were anastomosed to the ori-
fices of the hepatic veins in a piggyback manner.  
Reconstruction of the hepatic artery was performed 
microscopically until 2005,  at which point the recon-
struction procedure was switched to direct anastomosis 
under a 3.5 × magnified surgical loupe due to the ratio-
nalization of surgical job loading [7].  Mainly a hepati-
co-jejunostomy was chosen as the standard procedure 
for biliary reconstruction,  although a small number of 
duct-to-duct anastomoses were conducted for right lobe 
grafts.
The graft-type selection depended on the patient’s 
GRWR.  To avoid small-for-size graft-related mortality,  
right lobe grafts were selected in some recipients after 
2005.  Sixty percent (36 cases) of the grafts were lateral 
segment grafts.  Extended lateral segment and left lobe 
grafts (excluding or including the Spiegel lobe) com-
prised 20% and 18% of grafts,  respectively.  Four pedi-
atric patients of good physique underwent transplanta-
tion using a right lobe graft.  Segment 2 mono-segment 
grafts (requiring additional in situ reduction procedures) 
were introduced in 2010,  and were used for four small 
infants with estimated GRWRs > 5%.
When the post-explanted abdominal capacity 
seemed smaller than the calculated graft volume,  com-
plete closure of the abdomen was abandoned and tem-
porary closure was achieved instead using skin flaps 
separated from the fascial layer.  Disrupted muscular 
layers under the skin flap were reconstructed after 
growth as the repair of the incisional herniation.  Each 
liver graft was maintained in University of Wisconsin 
solution until the expired liver of the recipient had been 
removed.
Immunosuppression. In the majority of the cases,  
immunosuppression was achieved using tacrolimus and 
corticosteroids.  Tacrolimus was administered orally 
from day 1 every 12 h or by a continuous intravenous 
infusion.  Oral target trough levels were maintained at 
> 10 ng/mL for the first 2 weeks,  7-10 ng/mL for the 
next 2 months,  and 5.5 ng/mL thereafter.  The whole-
blood concentration for the intravenous tacrolimus 
administration was 1.4-fold the oral target trough level 
to provide an almost equal area under the concentra-
tion-time curve.  When the recipient had a history of 
neurological symptoms or manifestation of posterior 
reversible encephalopathy syndrome,  cyclosporine was 
chosen as the main calcineurin inhibitor.
Methylprednisolone was administered at 10 mg/kg 
after graft reperfusion,  followed by twice-daily dosing 
at 1 mg/kg for the first 4 days,  and programmed pulse 
therapy at 0.5 mg/kg intravenously per day for the next 
3 days (days 5-7).  From day 8,  prednisolone was given 
orally,  starting with a dosage of 0.3 mg/kg/day and 
tapered over the first 12 months after LDLT.  The aim of 
including programmed pulse therapy was the early 
diagnostic treatment of steroid-resistant rejection and 
compensation for unsettled tacrolimus trough levels in 
the early post-transplant phase for pediatric recipients,  
who show a relatively high prevalence of ACR.  An epi-
sode biopsy sample was obtained whenever liver 
enzymes and/or the total bilirubin level were found to 
be elevated.
When the recipient suffered from SRR,  full-dose 
pulse therapy (20 mg/kg for 3 days) with recycle taper-
ing and/or T-cell deletion therapy using muromonab 
(until 2010) or thymoglobulin (from 2011) was per-
formed.  Thereafter,  mycophenolate mofetil was also 
administered at 10 mg/kg for 3-6 months.  We did not 
actively attempt withdrawal from immunosuppression,  
expecting operational tolerance.
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In cases of ABO-incompatible LDLT for children > 2 
years old additional immunosuppressants were given to 
inhibit humoral rejection.  The preoperative induction 
of replacement transfusion or plasma exchange,  and the 
preoperative administration of rituximab were per-
formed.  Oral cyclophosphamide was provided at 2 mg/
kg/day from 7 days before surgery,  switching to azathi-
oprine at 1 mg/kg/day or mycophenolate mofetil at 
10 mg/kg from 1 month after surgery.
Statistical analysis. JMP ver. 8 software (SAS 
Institute,  Cary,  NC,  USA) was used for all statistical 
analyses.  Data are presented as mean,  median,  and 
standard deviation for continuous variables.  Categorical 
data are presented as proportions.  Differences between 
groups were assessed using the Mann-Whitney U-test 
for continuous variables and Fisher’s exact test or the χ2 
test for categorical variables.  To investigate the impact 
of prognostic factors,  patient survival was calculated 
using the Kaplan-Meier method,  the log-rank test was 
used for the univariate analysis of perioperative risk 
factors.  Stepwise forward Cox regression modeling was 
used for the multivariate analysis of perioperative risk 
factors.  Hazard ratios (HRs) and 95% confidence inter-
vals were calculated.  Values of p < 0. 05 were considered 
significant.
Results
Among the preoperative factors including sex,  age at 
the time of transplant,  preoperative condition,  ABO 
blood type compatibility,  and history of major abdom-
inal surgery,  the univariate analysis revealed that the 
disease category of CS showed significantly better out-
comes than NCS (p = 0.0002).  As intraoperative factors,  
GRWR,  CIT,  WIT,  and blood loss were significantly 
associated with recipient survival (p = 0.0035,  0.0047,  
0.0122,  and 0.0055,  respectively).  The cut-off values 
for GRWR,  CIT,  WIT,  and blood loss calculated from 
a receiver operating characteristic analysis were 2.84,  
58 min,  50 min,  and 100.6 ml/kg,  respectively.  The 
graft type,  the ratio of explanted liver for recipient body 
weight,  the explanted/transplanted liver weight ratio,  
the performance of portal vein plasty,  microscopic 
arterial reconstruction,  and operation time were not 
significant prognostic factors affecting recipient sur-
vival.
Postoperatively,  the aforementioned programmed 
pulse therapy was constantly induced after the 7th pedi-
atric recipient.  Hepatic artery thrombosis (HAT) and 
hepatic artery stenosis (HAS),  which are life-threaten-
ing complications,  were not significantly associated 
with survival in this series because none of the four 
recipients who experienced HAT or HAS was lost.  One 
recipient who experienced simultaneous arterial and 
portal thromboses underwent an urgent re-transplant 
using a maternal liver graft 7 days after the initial LDLT 
of a paternal liver graft.  Two recipients experienced 
juxta-operational HAT within 24 h after the primary 
LDLT,  and both of them were saved by surgical 
re-anastomosis.  The fourth recipient (with HAS) suf-
fered from severe vascular rejection that caused the 
HAS,  which was detected by a tardy waveform on 
ultrasonography on postoperative day 5.  Although bal-
loon dilation was attempted to correct the patient’s HAS 
using an angiographic technique,  an unexpected rup-
ture of the dilatation balloon caused a disruption of the 
anastomosis and the completion of HAT.  However,  the 
arterial supply was maintained via a rapid and vigorous 
development of collateral arteries.
Portal vein stenosis occurred in five cases but was 
not identified as a significant factor in survival.  Among 
these 5 cases,  4 were successfully revised by percutane-
ous trans-hepatic portal dilation.  The fifth recipient 
died of progressing hepatic failure due to the failure of 
surgical repair of the portal vein stenosis.
The prevalence of ACR as proven by episode biopsy 
was 60%,  and eight patients (13.3%) developed SRR.  
No early graft failure resulted from uncontrolled ACR or 
SRR.  CMV infection was found in 50% of the recipi-
ents,  but was not a significant prognostic factor wors-
ening the recipients’ survival because all of the recipi-
ents who were identified as pp-65 antigen-positive were 
administered ganciclovir or valganciclovir to prevent 
life-threating CMV disease.
Six recipients (10%) manifested PTLD.  One infant 
who received an LDLT at 6 months earlier from an 
ABO-incompatible donor manifested high fever and 
dyspnea caused by PTLD of Waldeyer’s ring.  Since a 
sharp decrease in immunosuppressant doses led to fatal 
ABO-humoral rejection during chemotherapy,  that 
patient died of hepatic failure.  The other five recipients 
with PTLD were successfully treated by dose reduction,  
switching immunosuppressants,  and chemotherapy.  
PTLD was therefore also not a postoperative factor that 
significantly affected recipient survival (Table 2).
We conducted a multivariate analysis to analyze the 
570 Yagi et al. Acta Med.  Okayama　Vol.  72,  No.  6
December 2018 Zero-mortality Living Donor Transplantation for Pediatric Cholestatic Diseases 571
Table 2 Univariate analysis of perioperative factors aﬀecting the recipientsʼ survival
Factors
Values,
mean value
±SD
Range or % Number oflost patients
Cut-oﬀ value for
continuous
parameters
Odds
ratio
(95%CI)
P values
Preoperative factors
Sex
Male 27 45.0% 4
0.971
Female 33 55.0% 5
Recipient age at transplant (years) 3.25±4.1 (89d-16.5y) － － 0.1304
Disease category
Cholestatic disease 43 71.7% 2
0.0002＊
Non-cholestatic disease 17 28.3% 7
Preoperative condition
Outpatient 38 63.3% 2
0.7377
Admission 22 36.7% 7
ABO blood type combination
Identical or compatible 51 85.0% 7
0.4375
Incompatible 9 15.0% 2
Surgical history of abdominal 
surgery
0 or 1 43 71.7% 7
0.6338
2 17 28.3% 2
Intraoperative factors
Type of graft
Mono-segment (S2) 4 6.7%
Lateral segment 35 58.3%
Left lobe 12 20.0%
Extended left lobe 6 10.0%
Right lobe 3 5.0%
Explanted liver/recipient body 
weight ratio 4.20±1.8 (1.00-8.71) － － 0.1343
GRWR 2.84±1.12 (1.00-6.16) 2.34 －2.91 0.0035＊
Explanted/transplanted
liver weight ratio 1.56±0.57 (0.36-3.07) － －
Cold ischemic time
(CIT,  min) 79.7±67.3 (7-373) 58 －0.0326 0.0047
＊
Warm ischemic time
(WIT,  min) 43.9±15.4 (20-102) 50 －0.1122 0.0122
＊
Portal vein plasty
yes 21 35.0% 2
0.9511
no 39 65.0% 7
Microscopic reconstruction of
hepatic artery
yes 19 31.7% 4
0.9326
no 41 68.3% 5
Blood loss (ml/kg) 100.6±122.4 (2.7-597.0) 22.5 0.0055 0.0055＊
Operation time (min) 529±169.0 (353-1154) － － 0.32
Postoperative factors
Programmed pulse therapy
yes 54 90.0% 9
0.265
no 6 10.0% 0
Hepatic artery thrombosis or
stenosis
yes 4 6.7% 0
0.2453
no 56 93.3% 9
Portal vein stenosis
yes 5 8.3% 1
0.4139
no 55 91.7% 8
Acute cellular rejection
(ACR)
yes 36 60.0% 7
0.8618
no 24 40.0% 2
Steroid-resistant rejection
(SRR)
yes 8 13.3% 1
0.633
no 52 86.7% 8
CMV infection
yes 30 50.0% 5
0.0996
no 30 50.0% 4
Post -transplant lympho -
proliferative disease (PTLD)
yes 6 10.0% 8
0.3141
no 54 90.0% 1
5 perioperative factors identified as significant by the 
univariate analysis.  The disease category of CS 
remained as the only independent predictor of better 
prognosis (p = 0.0021,  Table 3).  The overall survival 
among the 60 recipients was 91.4% at 1 year,  and 85.9% 
at both 3 and 5 years.  Since the only re-transplant case 
showed HAT-related early graft loss and since that 
re-transplanted recipient was doing well,  we evaluated 
the outcomes of our series based solely on patient sur-
vival.  The 1-,  3-,  and 5-year survival rates by group 
were 100%,  97.7%,  and 97.7% in the CS group,  and 
70.6%,  70.6%,  and 58.8% in the NCS group,  respec-
tively (Fig. 1).  Two recipients were lost in the CS group;  
one to viral infection,  and the other to chronic hepatic 
failure due to poor medication originating from paren-
tal neglect.  In the NCS group,  6 of the 9 lost patients 
experienced acute or chronic hepatic failure.  Of note,  
in the NCS group,  hepatocellular liver failure requiring 
urgent LDLT included some cases of incurable systemic 
disease and malignant tumor.  In the NCS group,  the 
early loss of three recipients resulted from the recur-
rence of malignant tumors (chronic active Epstein-Barr 
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Table 3 Multivariate analysis of prognostic factors
Factors Exp. Standard error Conﬁdential interval P-value
Cholestatic/non-cholestatic 1.255 0.4577 0.4372837＜  CI＜
2.3037148
 0.0021＊
GRWR 0.556 0.4045 －0.228276＜  CI＜
1.3883422
0.1644
CIT (min) －0.01 0.0131 －0.040273＜  CI＜
0.0109811
0.407
TIT (min) －0.071 0.0434 －0.167739＜  CI＜
0.0046094
0.0679
Blood loss (ml/kg) 0.00157 0.00287 －0.004872＜  CI＜
0.0070256
0.5927
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Group / % survival 1 year 3 years 5 years
Total (n=60) 91.4 85.9 85.9
Cholestatic (n=43) 100 97.4 97.4
Non-cholestatic (n=17) 70.6 58.8 58.8
Cholestatic (n=43)
Non-cholestatic (n=17)
p=0.0002, log-rank test
Fig. 1 Survival curves for the 60 pediatric recipients.  The overall survival at 1-,  3-,  and 5 years were 91.4%,  85.9%,  and 85.9%,  respec-
tively.  The survival rates for the cholestatic (CS) group vs. non-cholestatic (NCS) groups at 1,  3,  and 5 years were 100% vs. 70.6%,  
97.4% vs. 58.8%,  and 97.4 vs. 58.8%,  respectively.  Signiﬁcant diﬀerences in survival rates were seen between the CS and NCS groups 
(p=0.0002,  log-rank test).
virus infection-associated diffuse T and natural killer 
cell lymphoma,  and hepatoblastoma) and multi-organ 
failure from mitochondrial myopathy,  encephalopathy,  
lactic acidosis,  and stroke-like episodes (MELAS) 
[8 , 9].  Interestingly,  85.7% of the lost recipients in the 
NCS group experienced ACR (Table 4).
To clarify the characteristics of CS associated with 
better prognosis,  we analyzed the influences of disease 
category on perioperative factors.  A history of multiple 
major surgeries (p = 0.0042),  a larger ratio of explanted 
liver for recipient body weight (p = 0.0449),  a high fre-
quency of portal plasty (p = 0.0193),  longer total opera-
tion time (p= 0.0335),  and elongated CIT (0. 0421) were 
significant in the CS group (Table 5).
Discussion
Pediatric LDLT,  currently the only alternative to 
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Table 4 Details of the 9 mortality cases
Disease
category Case Age Sex
ABO
compatibility Initial diagnosis Final diagnosis ACR
Survival
(months) Cause of death
Cholestatic
(CS) 1 2y2m M Compatible BA BA ＋ 102.7
Hypoxic encephalopathy →
poor adherence
2 1y4m F Identical BA BA － 13.7 Inﬂuenza encephalo-pneumo-nitis
Non -
cholestatic
(NCS)
3 6m M Incompatible AHF AHF (unknown) ＋ 6.1 PTLD → dose down of CNI
→ humoral rejection (ABO)
4 1y6m F Identical Cryptogenic LC Tyrosinemia ＋ 12.7 Other cause of death
5 1y2m M Identical AHF AHF (unknown) ＋ 5 Portal stenosis → revision →portal obstruction
6 10m F Compatible Cryptogenic LC Cryptogenic LC ＋ 29 Cardiac failure
7 4y7m F Compatible Cryptogenic LC Chronic invasiveEB lymphoma＊ ＋ 2.5 MOF by tumor progression
8 8m F Incompatible AHF S/O MELAS＊ － 6.1 MOF by MELAS (deﬁned bymuscle biopsy)
9 2y M Identical Hepatoblastoma Hepatoblastoma ＋ 9.4 Lung metastasis
AHF,  acute hepatic failure; LC,  liver cirrhosis; EB,  Epstein-Barr; MOF,  multi-organ failure; MELAS,  mitochondrial myopathy,  encepha-
lopathy,  lactic acidosis,  and stroke-like episodes.
＊Out of indication for LT at postoperative ﬁnal diagnosis.
Table 5 Signiﬁcant factors aﬀected by disease category (except for recipient survival)
Disease category/Signiﬁcant factors Cholestatic group(n＝43)
Non-cholestatic group
(n＝17) P-value
Surgical history of
abdominal surgery
0 or 1 27 16 0.0042＊
over 2 16 1
Native liver/RBW ratio 4.494±1.641 3.449±2.101 0.0449＊
Operation time (min) 535.4±214 458.5±62.6 0.0335＊
Cold ischemic time (min) 88.0± 77.8 59.6±25.7 0.0421＊
Portal plasty 19/24 2/15 0.0193＊
＊Statistically signiﬁcant.
deceased donor LT,  has become accepted practice 
around the world because of its advantages including a 
lower pediatric waiting-list death ratio,  shorter waiting 
periods,  reduced ischemia times,  and more precise 
donor screening,  all of which contribute to better 
recipient survival [10 , 11].  Despite the clear increase in 
surgical complexity due to the preceding hepatopor-
toenterostomy (e.g.,  the extended surgical time and 
CIT),  the reasons for the good transplantation results 
for cholestatic cirrhosis warrant examination.
First,  the recipients in our CS group had mainly 
non-recurrent diseases,  with the exception of a small 
number of PSC recipients.  Three cases of death due to 
recurrence or progression of the primary disease after 
transplantation occurred in the NCS group.  These 
included a case of recurrent hepatoblastoma,  the devel-
opment of MELAS,  and liver invasion of EBV-derived 
malignant lymphoma.  Since the latter 2 recipients 
manifesting acute and subacute forms of hepatic failure 
were transferred to receive an urgent LT under an initial 
diagnosis of meeting LT indications,  their LDLTs were 
subsequently performed.  A histological diagnosis of 
both cases was obtained after the LT.  If these patients’ 
histological diagnoses had been obtained before the LT,  
both of them would have been excluded as LT candi-
dates.  Strong expectations from the patients’ families 
and referral doctors for LT,  the sudden onset of liver 
failure,  imminent symptoms,  and the temporal urgency 
for transplants led us to select immediate LDLT.
Fulminant hepatic failure is known to be a primary 
disease with poor prognosis among pediatric LT cases.  
The reported overall prognosis for children with acute 
liver failure remains poor,  with a mortality rate of 
44-67% [12-15].  We have lost 2 of 8 recipients with 
acute hepatic failure (AHF) among these 60 pediatric 
LDLT cases.  One recipient experienced respiratory fail-
ure that developed from Wardiel’s lymphoma 6 months 
after an ABO-incompatible LDLT.  However,  that 
patient died of hepatic necrosis due to the development 
of ABO-incompatible humoral rejection.  In the current 
rituximab era,  this case may be savable [16 , 17].  
Another patient showed strong stricture of the hepa-
to-duodenal ligament at the duct-to-duct anastomotic 
level after strong ACR and was lost due to portal vein 
occlusion after revision surgery on the bile duct.
Another factor contributing to better outcomes of LT 
in our CS group is the larger intraperitoneal space in the 
CS group.  Kasahara et al.  reported that the recipients 
under 1 year old who received grafts with a GRWR 
> 4.0% showed significantly worse survival [18].  
However,  as our data show,  patients with CS can accept 
a graft with a 1% greater GRWR compared to patients 
with NCS because of hepatomegaly due to cholestatic 
cirrhosis,  thus avoiding the risk of a large-for-size graft.  
Moreover,  the significant increase in the requirement 
for portal plasty shows that portal veins are narrower in 
the CS group compared to the non-CS group.  The rela-
tively high risk of portal vein complications among BA 
recipients reported by Takahashi et al.  may support a 
scarce portal feed and dominant arterial supply for the 
cirrhotic native liver before transplantation in a CS 
patient [19].  In other words,  the arteries in the present 
CS group were relatively thick and arterial complica-
tions may thus have been less likely to occur.  Whether 
arterial anastomosis was performed under fixed 
microscopy or a surgical loupe was not a prognostic 
factor for the recipients in our series.
Pediatric recipients are more likely to experience 
early acute rejection,  at approx.  twice the frequency of 
adults [20-22].  However,  this history of early acute 
rejection has some advantages,  inducing donor-specific 
hyporesponsiveness and improvement of both recipient 
and graft survival [23-25].  In terms of the pattern of 
postoperative hemodynamics early after LDLT,  a portal 
vein-dominant blood supply increases the port/arterial 
flow volume ratio to 8.3 in a deceased donor LT and to 
14.6 in an LDLT [26].  This portal hyperperfusion 
results in a relative decrease in arterial supply,  and is 
considered one contributor to the unique complications 
in LDLT,  termed “small-for-size syndrome” [27 , 28].
In early acute rejection,  portal hyperperfusion 
decreases as sinusoidal resistance rises,  and the arterial 
supply is secondarily enhanced by the hepatic artery 
buffer response [29-32].  This reciprocal increase in 
arterial blood flow may be favorable in maintaining 
patency of the anastomotic site in the early phase after a 
pediatric LT,  and may contribute to physically stable 
graft blood flow thereafter.
In conclusion,  pediatric CS disease required a more 
complicated surgical technique and significantly pro-
longed operation time,  but is very suitable for LDLT 
therapy and offers an excellent prognosis.  The further 
improvement of the survival of pediatric recipients 
requires the intensive prevention of the relapse of the 
patients’ primary disease and more rapid diagnoses in 
order to exclude contraindicated diseases which mani-
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fest hepatic failure as initial symptoms from NCS dis-
eases.
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